De antistof respons na pneumokokkenvaccinatie bij IBD-patiënten die behandeld worden met immunosuppressiva – de PNEUMOREACT studie
Recruiting
- Conditions
- inflammatory bowel disease (inflammatoire darmziekte)immunosuppressive agents (immunosuppressiva)pneumococcal vaccination (pneumokokkenvaccinatie)vaccine immunogenicity (vaccin immunogeniciteit)
- Registration Number
- NL-OMON29135
- Lead Sponsor
- Academic Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 188
Inclusion Criteria
Age > 18 years old
On treatment with an immunosuppressive agent or planned treatment start with a TNF-alpha inhibitor within 3 months after recruitment
Exclusion Criteria
Diagnosis of a primary immune deficiency disorder
Age < 18 years
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The ratio of the anti-pneumococcal antibodies measured before and four to six weeks after pneumococcal vaccination (T=week0 – PCV13 and T1= 8weeks – PPV23). An adequate response is considered as a 2-fold increase in anti-pneumococcal antibodies.
- Secondary Outcome Measures
Name Time Method The difference in response rates to pneumococcal vaccination between the control and intervention groups.